Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Tykerb Poised To Make Inroads Against Roche's Herceptin After Adding First-Line Indication

Executive Summary

GlaxoSmithKline's orally available cancer drug Tykerb (lapatinib) is poised to make inroads against Roche's Herceptin (trastuzumab) in the fight against one of the more deadly manifestations of metastatic breast cancer in post-menopausal women

You may also be interested in...

UnitedHealth Cancer Care Pilot Reduced Overall Costs Despite Higher Drug Spending

The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.

Korea FDA Approves Roche's Herceptin For First-line Metastatic Gastric Cancer

SEOUL - Korea FDA approved Roche's targeted anti-cancer drug Herceptin (trastuzumab) for first-line treatment of HER2-positive metastatic gastric cancer, providing a targeted therapy for the most common and leading cancer in Korea

Internet Promotions Must Be Redesigned After FDA Cites Sponsored Web Links

Firms will need to redesign sponsored links that appear on Internet search engines or forgo using them at all, food and drug attorneys suggest following the agency's recent cluster of letters citing the promotions





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts